Patrick Campbell is the senior editor of Practical Cardiology, as well as its sister publication Endocrinology Network. Prior to joining these brands, he led coverage of cardiology and diabetes with HCPLive. Before joining parent company MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a freelance multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. In his free time, he enjoys traveling, sports, and exploring the great outdoors. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
Data from a prespecified analysis of DAPA-CKD examining effects of dapagliflozin in patients with stage 4 CKD suggests the impact of the SGLT2 inhibitor in these patients was similar to those seen in the overall trial.
Analysis of more than 40k Medicare beneficiaries suggests increased physical activity, whether it occurs as part of a rehabilitation or not, was associated with decreased risk of all-cause mortality and hospitalizations for heart failure in patients who recently received an implantable cardioverter-defibrillator.
Analysis of data from the UK Biobank cohort suggests consumption of coffee was not linked to an increased risk of arrhythmias, with some evidence indicating habitual use was linked to a decrease in incidence of atrial fibrillation or flutter and supraventricular tachycardia.
A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.